iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux sold 43,883 shares of iTeos Therapeutics stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the transaction, the chief executive officer now owns 153,903 shares in the company, valued at $1,542,108.06. This represents a 22.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Michel Detheux also recently made the following trade(s):

• On Monday, June 9th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $440,136.46.
• On Monday, June 9th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.03, for a total value of $84,252.00.
• On Friday, June 6th, Michel Detheux sold 43,882 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $448,035.22.
• On Friday, June 6th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.21, for a total value of $85,764.00.
• On Wednesday, June 4th, Michel Detheux sold 43,883 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $443,218.30.
• On Wednesday, June 4th, Michel Detheux sold 8,400 shares of iTeos Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $84,840.00.

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $10.17 on Friday. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.13. The business has a 50-day moving average of $7.84 and a two-hundred day moving average of $7.54. The stock has a market capitalization of $389.25 million, a P/E ratio of -3.23 and a beta of 1.51.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. As a group, research analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Large investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth about $218,000. Empowered Funds LLC lifted its position in shares of iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth about $461,000. Virtu Financial LLC lifted its position in shares of iTeos Therapeutics by 84.3% during the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company’s stock worth $142,000 after purchasing an additional 8,460 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of iTeos Therapeutics during the 4th quarter worth about $142,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ITOS. JPMorgan Chase & Co. cut iTeos Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. HC Wainwright cut iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. Wedbush cut iTeos Therapeutics from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $10.00 to $12.00 in a research report on Wednesday, May 28th. Leerink Partners reissued a “market perform” rating and set a $9.00 price objective (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 28th. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, iTeos Therapeutics has a consensus rating of “Hold” and an average target price of $15.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.